Monday, October 27, 2025
- 10:30AM-12:30PM
-
Abstract Number: 1623
The Association of Calprotectin with Vascular Injury and Remodeling in Clinically-Isolated Aortitis
(1612–1632) Vasculitis – Non-ANCA-Associated & Related Disorders Poster II- 10:30AM-12:30PM
-
Abstract Number: 1415
The Association of Handedness with Radiographic Damage in Patients with Psoriatic Arthritis
(1405–1433) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II- 10:30AM-12:30PM
-
Abstract Number: 1319
The Association of Rheumatoid Arthritis in Patients with Vitiligo: Systematic Review and Meta-Analysis
(1306–1346) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II- 10:30AM-12:30PM
-
Abstract Number: 1516
The Benefits of SGLT2i on GFR Slope and Proteinuria in SLE Depend on Subgroups of Diabetes Mellitus and Baseline eGFR
(1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II- 10:30AM-12:30PM
-
Abstract Number: 1347
The Better Disease-modifying antirheumatic drug (DMARD)? Efficacy and Safety of Methotrexate Versus Leflunomide Monotherapy in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
(1347–1375) Rheumatoid Arthritis – Treatment Poster II- 10:30AM-12:30PM
-
Abstract Number: 0949
The Cancer-associated Female-biased Factor VGLL3 Drives Autoimmunity and Fibrosis
(0934–0954) Systemic Lupus Erythematosus – Animal Models Poster- 10:30AM-12:30PM
-
Abstract Number: 1043
The Care Pathway and Treatment Patterns in Patients with Uncontrolled Gout: A Real-World Survey of Physicians In The United States
(1038–1054) Health Services Research Poster II- 10:30AM-12:30PM
-
Abstract Number: 1517
The Chinese Experience with Telitacicept in Lupus Nephritis Management: 51-Patient Cohort Analysis on Therapeutic Outcomes and Safety Parameters
(1517–1552) Systemic Lupus Erythematosus – Treatment Poster II- 10:30AM-12:30PM
-
Abstract Number: 1227
The Composition of Circulating Immune Cells is Associated with Nociplastic Pain in Patients with Rheumatoid Arthritis
(1221–1247) Pain in Rheumatic Disease Including Fibromyalgia Poster- 10:30AM-12:30PM
-
Abstract Number: 1342
The Impact of Age on Health-Related Quality of Life in Patients With Rheumatoid Arthritis Compared to Population Controls: A Cross-Sectional Analysis
(1306–1346) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II- 10:30AM-12:30PM
-
Abstract Number: 1636
The Impact of Arthritis on Self-Management Activities of West Virginia Adults with Type 2 Diabetes During the COVID-19 Pandemic
(1633–1649) ARP Posters II: ARP Epidemiology & Public Health- 10:30AM-12:30PM
-
Abstract Number: 1409
The impact of depression in axial spondyloarthritis: Epidemiological insights from the Ankylosing Spondylitis Registry of Ireland (ASRI)
(1405–1433) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II- 10:30AM-12:30PM
-
Abstract Number: 1539
The Impact Of Interferon Signature On Anifrolumab Efficacy And Safety In Systemic Lupus Erythematosus: A Systematic Review And Meta-analysis
(1517–1552) Systemic Lupus Erythematosus – Treatment Poster II- 10:30AM-12:30PM
-
Abstract Number: 1136
The Impact of Iron Overload and HFE Genetic Mutations on Joint Disease in Haemochromatosis: Data from the Haemochromatosis Arthropathy Inception Cohorts